Grants and Contributions
About this information
In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.
The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.
Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.
$489,600.00
Mar 1, 2021
Individual or sole proprietorship
Operating Grant: COVID-19 Research Gaps and Priorities
158973
The objective is to invest in targeted COVID priority research areas from the Fall 2020 Project Grant competition such as vaccine hesitancy, pregnant women and children, racialized populations, Indigenous, confidence in science and SARS-CoV-2 variants.
$32,716,000.00
Mar 1, 2021
For-profit organization
Novocol Biomanufacturing Expansion Project (COVID-19)
815860
This project will support the expansion of existing bio-manufacturing facilities and increasing fill-finish capacity for vaccines/therapies, including live and viral vector vaccines.
$199,815.00
Mar 1, 2021
Academia
Mathematical modeling of SARS-CoV-2 life cycle and COVID-19 vaccine response
968659
This Project proposes a modeling platform to quickly explore vaccine designs using simulation and Machine Learning algorithms.
$27,000.00
Feb 23, 2021
Not-for-profit organization or charity
Contribution to Rotary Club of Grenada East
16886
Conduct an Education Empowerment Drive on COVID 19 and COVID 19 Vaccine for All categories of Health Workers both in the private and public health sectors and of The Media in Grenada, Carriacou and Petite Martinique through Training workshops and sensitization sessions.
$492,387.00
Feb 7, 2021
Academia
Development of a scalable upstream process for SARS-CoV-2 spike protein production in bioreactors
965937
The spike protein (S protein) of the pandemic coronavirus (SARS-CoV-2) is the antigen of choice for use in vaccines and serological diagnostic tests. There is thus a pressing need to develop a robust bioprocess allowing scale-up of spike protein production.
$50,000.00
Feb 1, 2021
For-profit organization
Development of T Cell Immunoassay for COVID-19 and other diseases
964595
The project will involve the development of a diagnostic test to detect anti-SARS-CoV-2-specific T cells in a small sample of peripheral blood with initial aim to test vaccine effectiveness in terms of cell mediated immunity and understand which vaccine recipients are potentially immune to COVID-19 to triage vaccine prioritization in Canada.
$742,264.00
Feb 1, 2021
For-profit organization
Vaccine Development for Canadian aquaculture
969357
This project will seek to redevelop two approved vaccines for farmed salmonids in Canada. This life cycle management project will introduce an antigen to both vaccines and offer a new indication to the market.
$303,341.00
Jan 21, 2021
Academia
Newcastle Disease Virus (NDV) as a novel platform for development of COVID-19 vaccines
964417
The University of Guelph developed a vaccine to protect against the novel coronavirus disease that emerged in 2019 (COVID-19) using a safe vector known as avian orthoavulavirus-1 (AOaV-1) with a transgene encoding the full-length spike protein (FLS) from severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). In a hamster challenge model of COVID-19, intranasal vaccination with AOaV-1-FLS completely protected against disease, and SARS-CoV-2 could not be detected.
$303,341.00
Jan 21, 2021
Academia
Newcastle Disease Virus (NDV) as a novel platform for development of COVID-19 vaccines
964417
The University of Guelph developed a vaccine to protect against the novel coronavirus disease that emerged in 2019 (COVID-19) using a safe vector known as avian orthoavulavirus-1 (AOaV-1) with a transgene encoding the full-length spike protein (FLS) from severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). In a hamster challenge model of COVID-19, intranasal vaccination with AOaV-1-FLS completely protected against disease, and SARS-CoV-2 could not be detected.
$199,159,000.00
Nov 20, 2020
For-profit organization
Coronavirus/Pandemic Vaccine/Treatment Manufacturing Capacity
816022
This project will help develop Canada's medical countermeasures to COVID-19 and future pandemics by expanding RBI's manufacturing capabilities to create additional vaccine, therapy and fill/finish capacity at its Mississauga, Ontario site.